Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2012 2
2013 1
2016 1
2018 2
2019 1
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group. Kellokumpu-Lehtinen PL, et al. Among authors: hervonen p. Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4. Lancet Oncol. 2013. PMID: 23294853 Clinical Trial.
Inflammation of actinic keratoses after docetaxel.
Kluger N, Rentola L, Hervonen P, Lappalainen K. Kluger N, et al. Among authors: hervonen p. Presse Med. 2018 Jun;47(6):598-599. doi: 10.1016/j.lpm.2018.01.023. Epub 2018 Mar 17. Presse Med. 2018. PMID: 29555171 No abstract available.
[Testicular cancer].
Raitanen M, Hervonen P. Raitanen M, et al. Among authors: hervonen p. Duodecim. 2005;121(7):743-50. Duodecim. 2005. PMID: 15909961 Review. Finnish. No abstract available.
Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019.
Karttunen E, Hervonen P, Hosseini Aliabad A, Oldenburg J, Pappot H, Sairanen J, Støvring H, Vásquez JL, Bergman S, Magnussen G, Norremark P, Thoresen S, Ullén A. Karttunen E, et al. Among authors: hervonen p. Scand J Urol. 2023 Feb-Dec;57(1-6):15-21. doi: 10.1080/21681805.2022.2138965. Epub 2022 Nov 23. Scand J Urol. 2023. PMID: 36416403
The clinical impact of using complex molecular profiling strategies in routine oncology practice.
Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H. Laes JF, et al. Among authors: hervonen p. Oncotarget. 2018 Apr 17;9(29):20282-20293. doi: 10.18632/oncotarget.24757. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755651 Free PMC article.
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Kellokumpu-Lehtinen PL, Marttila T, Jekunen A, Hervonen P, Klintrup K, Kataja V, Utriainen T, Luukkaa M, Leskinen M, Pulkkanen K, Kautio AL, Huttunen T. Kellokumpu-Lehtinen PL, et al. Among authors: hervonen p. Anticancer Res. 2020 Dec;40(12):6915-6921. doi: 10.21873/anticanres.14715. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288585 Clinical Trial.
12 results